InfuSystem (INFU) Q2 2026 Earnings Call Transcript
InfuSystem (INFU) reported Q2 2026 revenue of $36.9 million, up 2.6% year over year, including a $1.6 million revenue reduction from a GE Healthcare biomedical services contract restructuring. Adjusted EBITDA rose 7.6% to $8.6 million, with margin at 23.4%. Oncology revenue grew 6.4% and Wound Care rose 154%. The company expects 2026 pro forma revenue growth of 6% to 8% and adjusted EBITDA margin in the low-to-mid 20% range.
How this was made
The 30-second read
Why it matters
The call frames a path to continued profitable growth: Oncology revenue surpassed $20M for the first time, Wound Care net revenue surged 154% driven by compression devices, and management reiterated a 6% to 8% annual revenue growth range on a pro forma basis with adjusted EBITDA margin in the low-to-mid 20% range.
Market read
Traders can update models for INFU using the disclosed Q2 financials, segment drivers, and the explicit pro forma FY revenue growth and margin guidance for the remainder of 2026.
What to watch
Device Solutions revenue declined 16.1% and equipment sales fell 49% due to a prior rental customer buyout, which may cap upside despite stable gross profit.
Background
InfuSystem’s Q2 2026 earnings call discusses segment performance (Oncology, Wound Care, Device Solutions), the GE Healthcare biomedical services contract restructuring, ERP stabilization progress, and 2H/FY outlook.
Ticker impact
InfuSystem reported Q2 revenue of $36.9M, adjusted EBITDA of $8.6M, and guided FY revenue growth of 6% to 8% on a pro forma basis after GE restructuring.
Moderately positive near-term bias if investors focus on the 6% to 8% pro forma growth outlook and stable gross margin/margin expansion.
The article includes multiple current-quarter results (revenue, EBITDA margin, segment growth) plus explicit 2H/FY guidance ranges, which are actionable for positioning around the next earnings cycle.
Market effects
Signals continued demand strength in outpatient oncology infusion and rapid Wound Care device growth, potentially supportive for DME/infusion peers’ sentiment.
No specific regional read-through provided.
Primarily US healthcare services and device manufacturing partnerships; limited global spillover.
Counterpoint
Pro forma growth guidance is explicitly adjusted for the GE Healthcare contract restructuring, so headline growth may look weaker and could disappoint if investors anchor to GAAP revenue.
Key entities
- companyInfuSystem
Reported Q2 2026 results and provided pro forma FY revenue growth and adjusted EBITDA margin expectations.
- counterpartyGE Healthcare
Biomedical services contract restructuring reduced Q2 revenue by $1.6M and is used to adjust pro forma growth outlook.
